Macrogen

Macrogen OCF Margin

The Operating Cash Flow Margin of Macrogen (038290.KQ) as of Oct 29, 2026 is 11.44 %. In the previous year, Operating Cash Flow Margin was 5.25 % — a change of 118.12% (higher).

OCF Margin

11.44 %

YoY

118.12%

Last updated:

Operating Cash Flow Margin of Macrogen is 2025 11.44 % . Operating Cash Flow Margin of Macrogen was 2024 5.25 % . It decreases by 118.12% higher compared to the previous year.

The Macrogen OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
13.83 KRW
Jan 1, 2019
11.86 KRW
Jan 1, 2020
18.25 KRW
Jan 1, 2021
16.40 KRW
Jan 1, 2022
7.77 KRW
Jan 1, 2023
3.59 KRW
Jan 1, 2024
5.25 KRW
Jan 1, 2025
11.44 KRW
The Macrogen OCF Margin history
YEAROCF MarginYoY
11.44 %+118.12%
5.25 %+46.22%
3.59 %-53.80%
7.77 %-52.64%
16.40 %-10.15%
18.25 %+53.93%
11.86 %-14.28%
13.83 %+7.75%
12.84 %-44.95%
23.32 %+159.21%
9.00 %-26.03%
12.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Macrogen Stock analysis

What does Macrogen do? Macrogen Inc. generates revenue through its four business divisions. The DNA sequencing division provides genome sequencing analysis services to clients requiring genetic data processing. The DNA chips division sells products including Illumina chips, MacArray chips, and customized chips to research institutions and biotech firms. The transgenic and knockout mouse division offers gene engineering services to pharmaceutical companies and academic laboratories. The oligonucleotide DNA division supplies oligonucleotide DNA manufacturing services to biotechnology clients. All services are delivered domestically and internationally to established market segments. The company's DNA chips division markets specific branded products like Illumina chips and MacArray chips, which are purchased by research organizations and biotechnology enterprises. Gene engineering services from the transgenic division are bought by pharmaceutical companies seeking to develop new treatments. Oligonucleotide DNA manufacturing services target biotech clients needing specialized DNA synthesis. Domestic and overseas markets represent the primary customer segments for all divisions. Macrogen's product portfolio includes DNA sequencing services, DNA chip products, gene engineering solutions, and oligonucleotide DNA manufacturing. Clients include research institutions, pharmaceutical companies, academic laboratories, and biotechnology firms. The DNA chips division's branded products are specifically named in the description, while other services are described by their technical functions. Market segments are defined by the company's domestic and international operations. Macrogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Macrogen stock

Operating Cash Flow Margin of Macrogen is 11.44 % in 2025.

Operating Cash Flow Margin of Macrogen changed from 5.25 % to 11.44 %, representing a 118.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Macrogen since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Macrogen with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Macrogen

All Key Metrics — Macrogen